Aspect Biosystems Ltd., a Vancouver startup developing ... but it still has further preclinical R&D to do before it can test its creations in humans. Aspect chief executive officer and co-founder ...

We now have three facilities over 34,000 square feet. We opened the last another lab 2,000 square feet CL-2 containment QC and R&D, the Berkeley to build our capacity and our portfolio of product ...

During the development of the olfactory epithelium (OE), olfactory sensory neurons (OSNs) express only one member of the odorant receptor (OR) gene family, and O ...

Selbyville, Delaware, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ...

Assays were performed in duplicate with a TNF-R1 specific ELISA kit (R & D Biosystems, Minneapolis, MN). 2.4. RNA Isolation and Reverse Transcription RNA was isolated using an RNAeasy kit with ...

LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance ...

Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ ... bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth ...

Aspect Biosystems raises $115M Series B for bioprinted tissue therapeutics targeting diabetes and metabolic disorders, led by ...

Vancouver-based Aspect Biosystems has raised a $115-million USD ($165 million CAD) Series B round to realize its ambitions of bringing 3D-printed tissue therapies into clinical use. Aspect has ...

(RTTNews) - T2 Biosystems, Inc. (TTOO), a Massachusetts-based biotechnology company, on Tuesday reported its preliminary financial and operational results for the fourth quarter and full year ...